InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV)
InVivo Therapeutics Holdings Corp. (OTCMKTS:NVIV) jumped another 21.35% yesterday, as it announced that the largest regional trauma center in St. Louis is to be the new clinical trial site for its study.
NVIV skyrocketed last Wednesday with the announcement that the first subject has been enrolled in its research on complete traumatic spinal cord injury. With this in mind, it isn’t that much of a surprise that the company’s stock prices jumped once more when it became known that the tests will be carried out in the Barnes-Jewish Hospital at Washington University.
Indeed, enlisting an esteemed specialist, such as Dr. Paul Santiago, an Associate Professor of Neurological and Orthopedic Surgery at the Washington University School, as the study’s Principal Investigator can be considered an excellent and timely move. NVIV is certainly going to need the help of professionals like him in order to perfect its Neuro-Spinal Scaffold technology and make it marketable.
All in all, NVIV seems to be making the right moves. The biggest concern for investors at the moment should probably be the time it will take for NVIV to roll out its flagship product. Medical OTC Markets companies tend to be stuck in the development stage for years on end, and even if NVIV is an exception to the norm it will probably still take quite a bit of time for the company to become commercially successful.
The good news is that it looks like until that day comes, NVIV will be in sound and caring hands . Currently it seems well managed, and it clearly doesn’t suffer from many of the faults that usually afflict medical stocks in similar stages of development.
This fact gives many investors and analysts alike high hopes that when the company makes it, it will make it big.